Luiz Roberto Castello-Branco holds a degree in Medicine from Souza Marques University in Rio de Janeiro, a residency in General Surgery at Ipanema Hospital, a Master’s degree in General Surgery from the Federal University of Rio de Janeiro, and a Ph.D. in Clinical Immunology from the University of London, England. He has experience in the field of Immunology, with an emphasis on Mucosal Immunology and prevention, primarily working on HIV/AIDS, Tuberculosis, and Vaccines. He was the head of the Clinical Immunology Laboratory at the Oswaldo Cruz Institute/Oswaldo Cruz Foundation, a member of MUVAPRED (Mucosal Vaccines For Poverty Related Diseases) of the European Economic Community, coordinator of the Vaccine area at the National Institute of Science and Technology in Tuberculosis, a member of the Technical Chamber of Immunobiologics of the Ministry of Health, and a member of the BCG Vaccine Committee of the WHO. He has conducted research that resulted in patents related to BCG and diagnostic tests, in addition to coordinating the team that developed and launched the product “ImunoBCG” for the treatment of superficial bladder cancer. Responsible for the international certification of the strain and the BCG vaccine Moreau Rio de Janeiro, as well as its designation as a Reference Reagent in the WHO portfolio. Technical responsible for the technology transfer of this immunotherapeutic (ImunoBCG), owned by the Ataulpho de Paiva Foundation, to the Spanish Company BIO-CZV.Currently, he is the Executive Director of the Ataulpho de Paiva Foundation.